. Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849.
PMID: 37703508